3 replies to this topic

[onz]

The next guest on our Longecity podcast is James Clement, President and Director of betterhumans.org - "the world's first specifically-transhumanist bio-medical research organization"

 

 

Betterhumans is about to join Longecity's affiliate labs scheme, and for good reason too, their mission is passionately aligned with goals of our community. Here's a quote from their website:

 

The human body is an amazing product of natural selection and evolution. But evolution operates too slowly for 21st Century Man, and it will now become the platform for a host of upgrades that extend human capabilities beyond what Nature has provided so far. Guided by the Proactionary Principle, Betterhumans will strive to radically extend healthy lifespans, end human diseases, improve human cognition and wellbeing, and allow us to upgrade those biological features that are important to us.

 

Human safety is of the highest importance to us. That’s why we are performing tests on non-human mammals first. In our lab now, we are conducting gene-therapy and stem cell experiments on mice. In the near future we will take what we’ve learned and apply them to mammals more similar to humans, and as soon as we safely can, we will run pilot human clinical trials.

 

Our goal, as a non-profit, is to develop therapies that can be offered at the lowest cost possible. Stem cell transplants and gene therapy upgrades (such as improved health and lifespan) should not cost you the equivalent of buying a car, it should be as affordable as a new cell phone or laptop. We hope to pioneer storefront clinics that can provide these upgrades so that anyone over the age of 65 can afford them, and can participate in the wave of Exponential Technology in the bio-medical field that will propel us into an unlimited future of lasting health and youth. All discoveries will be offered under a Creative Commons Public Patent License format, or the equivalent.

 

 

​Let us know your questions in the comments below! We'll schedule the interview in a couple of weeks to give you guys some time

 

 

 

 

 

Edited by caliban, 14 October 2017 - 02:20 PM.
sp.

[Heisok]

Thank you very much Onz!

 

I hope you do not mind, but I looked over the site, and maybe this information might get some members interested, and I hope with many questions for the interview.

 

Supercentenarian Study

 

The object of the Betterhumans Supercentenarian Research Study is to compare genomic and molecular data from extremely long-lived individuals among themselves (seeing what’s similar) and with “normal” individuals, especially those who died having known illnesses, such as cancer, cardiovascular diseases, Alzheimer’s, stroke, diabetes, etc. (seeing what’s different).

For more information, please visit the Betterhumans Supercentenarian Research Study website.

 

 

 

 

Human Pilot Studies

We intend to pursue many small scale human pilot studies to test the safety and efficacy of various FDA-approved drugs and therapies thought to have anti-aging effects. We will publish all results so that other researchers, physicians, and patients can have information which may aid their efforts.

IRB-Approved Clinical Pilot Studies

• NAD+. The purpose of this Phase-0 pilot study is to determine the pharmacokinetics and efficacy of molecules known to raise or maintain plasma and intracellular levels of NAD+ in humans, and to study the effects of NAD+ on various biomarkers of aging, age-related diseases, neurological disorders, and metabolic syndrome. We will administer different combinations of precursor molecules of NAD (e.g., nicotinamide riboside (“NR”) and nicotinamide mononucleotide (“NMN”)) and intravenous, subcutaneous, and/or intramuscular NAD+ to determine whether Topical, IV, Subq, or IM NAD+ and/or oral precursors NR or NMN will significantly increase cellular concentrations of NAD+, improve the NAD/NADH ratio, favorably change metabolic biomarkers, and upregulate expression of the anti-aging genes in elderly individuals who have Metabolic Syndrome or any of the following pathologies: Parkinson’s, Alzheimer’s, Traumatic Brain Injury, Post-Traumatic Stress Disorder, “Chemo-Brain,” Major Depression, or Stroke.

• Senolytic Compounds: The question seeking to be answered by this Phase 0 pilot study is whether the senolytic compounds Dasatinib (CAS no. 302962-48-8) and Quercetin (CAS no. 117-39-5) will significantly eliminate senescent cells contained in the muscle and fat tissue of elderly individuals who have Metabolic Syndrome and/or Osteoarthritis, and will reduce levels of systemic inflammation, insulin resistance, improve their immunological responses, and in those having Osteoarthritis, reverse the progression of this disease.

• Rapamycin: The purpose of this Phase-0 pilot study is to determine the safety and efficacy of rapamycin for improving biomarkers for metabolic-disorders, inflammation, DNA-damage repair, and mitochondrial dysfunction in humans. The hypothesis of the Principle Investigator and Study Physician is that dose-timing to avoid high trough concentrations will result in inactivation only of mTORC1 and not mTORC2, thus avoiding the immunosuppression, insulin resistance, and other adverse events that accompany mTORC2 inactivation. We will thus administer rapamycin (Rapamune/Sirolimus) over a range of doses and periods of time to attempt to minimize adverse effects (see Safety) but maximize the positive effects described above.

[onz]

That's great thanks Heisok!

 

We have a few extra weeks up our sleeves as James would prefer to conduct the podcast after an upcoming article in the New York Times

[Maidenhead]

thanks for the podcast. it's interesting